Mutation and inactivation of TSC1, such as those frequently observed in bladder cancer cells leads to hypoacetylation of Hsp90, enhanced ATPase activity, and reduced binding to inhibitors (Figure 5E). The gene discussed is TSC1; the disease is urinary bladder carcinoma.